中文

Veracyte (VCYT)

Healthcare

Close on Nov 5, 2026 (from our latest article): $24.00

Market value
$1.9Bat the Nov 5 close
Revenue growth
+17%12 months to Sep 30, 2026 (10-Q)
FCF margin
28%12 months to Sep 30, 2026 (10-Q)
Net cash
$371Mat Sep 30, 2026
Worst fall since listing
−81.2%Feb 9, 2021 to Oct 20, 2022; not back to that high (−69.2% now)

About the company

Latest

  • Down 54.3% Move
    Veracyte falls 54% as its prostate test growth target is cut

The Long View

What the filings say about the story, dilution and cash runway.

No Long View yet. Request one →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

More of our coverage that names Veracyte

Long-term fundamentals

Annual results for Veracyte, FY2011–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $3M in FY2011 to $517M in FY2025. Free cash flow was positive in 3 of the 15 years shown; FY2025: $127M. Each year's figures are in the table below. −$200M$0$200M$400M$600M ’11 ’13 ’15 ’17 ’19 ’21 ’23 ’25

Revenue went from $3M in FY2011 to $517M in FY2025.

Free cash flow was positive in 3 of the 15 years shown; FY2025: $127M.

Margins

Operating margin was 11% in FY2025, vs −30% in FY2020. Gross margin was 70% in FY2025, vs 59% in FY2022. Each year's figures are in the table below. −600%−400%−200%0%200% ’11’13’15’17’19’21’23’25

Operating margin was 11% in FY2025, vs −30% in FY2020.

Gross margin was 70% in FY2025, vs 59% in FY2022.

Diluted share count

The diluted share count rose 51% from FY2020 to FY2025, to 81M. Each year's figures are in the table below. 40M50M60M70M80M90M ’19’20’21’22’23’24’25

The diluted share count rose 51% from FY2020 to FY2025, to 81M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$517M70%11%$66M$136M$10M$127M
FY2024$446M67%4%$24M$75M$11M$64M
FY2023$361M64%−24%−$74M$44M$10M$34M
FY2022$297M59%−14%−$37M$8M$9M−$1M
FY2021$220M—−37%−$76M−$32M$5M−$37M
FY2020$117M—−30%−$35M−$10M$3M−$13M
FY2019$120M—−13%−$13M−$3M$3M−$6M
FY2018$92M—−24%−$23M−$14M$2M−$15M
FY2017$72M—−37%—−$24M$2M−$26M
FY2016$65M—−44%—−$28M$4M−$32M
FY2015$50M—−68%—−$27M$6M−$33M
FY2014$38M—−76%—−$28M$2M−$30M
FY2013$22M—−106%—−$19M$1M−$20M
FY2012$12M—−163%—−$7M$1M−$9M
FY2011$3M—−577%—−$14M$0.3M−$14M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202581M$413M—$44M——
FY202478M$289M—$36M——
FY202373M$216M—$33M——
FY202272M$179M—$27M——
FY202168M$173M$1M$23M——
FY202053M$349M$0.8M$13M——
FY201946M$159M$0.7M$10M——
FY2018—$78M$25M$6M——
FY2017—$34M$25M$7M——
FY2016—$59M$25M$6M——
FY2015—$39M$5M$6M——
FY2014—$35M$5M$4M——
FY2013—$71M$5M$1M——
FY2012—$14M————
FY2011—$8M————

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 5, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearVCYTS&P 500
2019+121.9%+31.5%
2020+75.3%+18.4%
2021−15.8%+28.7%
2022−42.4%−18.1%
2023+15.9%+26.3%
2024+44.0%+25.0%
2025+6.3%+17.9%
2026 to date−40.5%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Healthcare

Questions about Veracyte

Why did Veracyte stock fall on Nov 5, 2026?
Veracyte beat third-quarter forecasts, but its main product, the Decipher prostate cancer test, fell short of its own expectations again, and it expects only mid-single-digit revenue growth in 2027 after about 15% this year. The shares fell about 54%, their biggest one-day fall in at least 10 years (Nasdaq closes, our calculation), on a day the S&P 500 fell 4.4%. They were already down more than 40% at the open; no source we found explains the further slide, though the market's fall may have added to it. Read the article →